Polygenic risk score may identify more clinically significant PCa than PSA, MRI
April 10th 2025"Building on decades of research into the genetic markers of prostate cancer, our study shows that the theory does work in practice—we can identify men at risk of aggressive cancers who need further tests and spare the men who are at lower risk from unnecessary treatments," says professor Ros Eeles.
Genetic test can predict risk of toxicity following radiation for prostate cancer
April 7th 2025"This finding reinforces PROSTOX ultra as a true measure of the biological response to radiation, independent of treatment era or technique that can identify the safest course of treatment to avoid toxicity," says Amar U. Kishan, MD.
Avoidance of prostate cancer screening linked to increased risk of PCSM
March 21st 2025“Our study identifies that men who were invited for screening, but do not attend screening appointments are at significantly higher risk of dying from prostate cancer compared to men who were not offered screening or accepted an invitation for screening,” says Renée Leenen MD.
Exercise may improve erectile function in men with prostate cancer
March 17th 2025“The study suggests that exercise would be an effective intervention for men with prostate cancer who express concern about sexual dysfunction, and that exercise medicine should be considered a key part of their treatment,” says Daniel Galvão, PhD.
Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer
March 17th 2025"4 years following radiation therapy, there is a 25% lower hazard of bowel disorders and a 46% lower hazard of related procedures [in patients who received a spacer],” says Michael R. Folkert, MD, PhD.
Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC
March 10th 2025"Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined approach is an optimal option in selected patients with metachronous oligorecurrent hormone-sensitive prostate cancer," the authors wrote.